Biogen

cellos without players
Biotech

UCB-Novartis Parkinson's asset fails to improve symptoms in ph. 2

UCB’s Novartis-partnered oral small molecule has failed to improve symptoms of Parkinson’s disease in a phase 2 trial.
Gabrielle Masson Dec 16, 2024 3:19pm
Paraglider over French coast

Biogen boosts C-suite with BMS vet—Chutes & Ladders

Nov 1, 2024 8:30am
Bottle of glue

Biogen buys in to molecular glues with deal worth up to $1.45B

Oct 30, 2024 10:50am
Deal terminate tear up end deal scrap

Biogen cans SAGE-324 collaboration after essential tremor fail

Sep 26, 2024 9:00am
An arrow incrementally going up stairs before pointing straight up Blue background

Biogen, UCB report phase 3 lupus win after failing earlier trial

Sep 24, 2024 6:00am
rhino charge bold attack full speed

Biogen CEO said no risky deals in 2023. Now he’s ready to be bold

Aug 1, 2024 10:34am